Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 5:19 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 835 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Intramuscular vaccine Clear all

Conditions: HIV Infections
Interventions: Quadrivalent HPV Vaccine, Placebo Vaccine for Male Participants Only, Placebo Vaccine for Female Participants Only; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 27 Years and older
Enrollment: 575 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 22
States / cities: Los Angeles, California • Palo Alto, California • San Diego, California + 14 more

Conditions: Influenza, Healthy Volunteers
Interventions: Trivalent (TIV) messenger ribonucleic acid (mRNA) hemagglutinin (HA) Vaccine 1, TIV mRNA-neuraminidase (NA), TIV mRNA-HA Vaccine 2, Quadrivalent Influenza Standard Dose Vaccine, Quadrivalent Influenza Vaccine High Dose; Biological
Lead sponsor: Sanofi Pasteur, a Sanofi Company; Industry
Eligibility: 50 Years and older
Enrollment: 1,162 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 21
States / cities: Birmingham, Alabama • Mobile, Alabama • Tempe, Arizona + 18 more

Conditions: Asthma
Interventions: PCV13, PPSV23; Biological
Lead sponsor: Mayo Clinic; Other
Eligibility: 19 Years to 64 Years
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Haemophilus Influenzae Type b, Neisseria Meningitidis
Interventions: GSK Biologicals' Haemophilus influenzae type b and Neisseria meningitidis serogroups C and Y-tetanus toxoid conjugate vaccine combined 792014, ActHIB, Pediarix/Infanrix Penta; Biological
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 6 Weeks to 12 Weeks
Enrollment: 4,432 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2008
U.S. locations: 61
States / cities: Birmingham, Alabama • Benton, Arkansas • Fayetteville, Arkansas + 51 more

Conditions: Multiple Myeloma
Interventions: Survivin Vaccine, Autologous Hematopoietic Cell Transplantation, Prevnar 13, Granulocyte-colony Stimulating Factor; Biological · Procedure · Drug
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Healthy
Interventions: ExPEC4V, Placebo; Biological
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 2
States / cities: Wichita, Kansas • Knoxville, Tennessee

Conditions: Intraocular Melanoma, Melanoma (Skin)
Interventions: mouse gp100 plasmid DNA vaccine, The Dermal PowderMed® devices, intramuscularly (IM injection); Biological · Device · Other
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 1 Year to 120 Years
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2011
U.S. locations: 1
States / cities: New York, New York

Conditions: Influenza
Interventions: Quadrivalent VLP Vaccine, Comparator TIV; Biological
Lead sponsor: Novavax; Industry
Eligibility: 18 Years to 49 Years
Enrollment: 400 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2015
U.S. locations: 5
States / cities: Anaheim, California • Miami, Florida • Lenexa, Kansas + 2 more

Conditions: Tetanus
Interventions: Adacel; Biological
Lead sponsor: GCAM Inc.; Industry
Eligibility: 18 Years to 63 Years
Enrollment: 110 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2021
U.S. locations: 2
States / cities: Eagle Pass, Texas • Laredo, Texas

Conditions: HIV Infections
Interventions: HIV-1 gag DNA, HIV-1 gag DNA plus IL-12 DNA adjuvant, CTL MEP/RC529-SE/GM-CSF (CTL MEP vaccine), Sodium chloride injection (0.9%); Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 50 Years
Enrollment: 144 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Ends 2008
U.S. locations: 3
States / cities: Birmingham, Alabama • Baltimore, Maryland • Nashville, Tennessee

Conditions: Clostridium Difficile Infection
Interventions: C. difficile Toxoid Vaccine, Placebo: 0.9% normal saline; Biological
Lead sponsor: Sanofi Pasteur, a Sanofi Company; Industry
Eligibility: 50 Years and older
Enrollment: 9,302 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2018
U.S. locations: 142
States / cities: Huntsville, Alabama • Mobile, Alabama • Flagstaff, Arizona + 124 more

Conditions: Participants With or Without Stable Co-morbidities Associated With Progression to Severe COVID-19 at Different Stages of the Protocol
Interventions: Ad26.COV2.S, Placebo; Biological · Other
Lead sponsor: Janssen Vaccines & Prevention B.V.; Industry
Eligibility: 18 Years and older
Enrollment: 44,325 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2023
U.S. locations: 117
States / cities: Birmingham, Alabama • Huntsville, Alabama • Glendale, Arizona + 77 more

Conditions: Measles-Mumps-Rubella
Interventions: Priorix, M-M-R II, Kinrix, ProQuad; Biological
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 4 Years to 6 Years
Enrollment: 4,011 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2015
U.S. locations: 50
States / cities: Birmingham, Alabama • Tucson, Arizona • Benton, Arkansas + 44 more

Conditions: Kidney Cancer
Interventions: human prostate-specific membrane antigen plasmid DNA vaccine, mouse prostate-specific membrane antigen plasmid DNA vaccine; Biological
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2018
U.S. locations: 1
States / cities: New York, New York

Conditions: Influenza
Interventions: H7N3 pLAIV, H7N9 pIIV; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 49 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Rochester, New York

Conditions: Head and Neck Cancer
Interventions: DNA Vaccine, Cyclophosphamide; Biological · Drug
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 18 Years to 75 Years
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Influenza
Interventions: mRNA-1010, mRNA-1010.4, mRNA-1010.6; Biological
Lead sponsor: ModernaTX, Inc.; Industry
Eligibility: 18 Years to 49 Years
Enrollment: 270 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023
U.S. locations: 10
States / cities: Hollywood, Florida • Miami, Florida • Lenexa, Kansas + 7 more

Conditions: COVID-19
Interventions: ChAdV68-S, ChAdV68-S-TCE, SAM-LNP-S, SAM-LNP-S-TCE, Sodium Chloride, 0.9%; Biological · Other
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 99 Years
Enrollment: 81 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2023
U.S. locations: 4
States / cities: Decatur, Georgia • St Louis, Missouri • Houston, Texas + 1 more

Conditions: Pertussis
Interventions: Pentacel® (DTaP-IPV/Hib), Other Pertussis Vaccines; Biological
Lead sponsor: Sanofi Pasteur, a Sanofi Company; Industry
Eligibility: Up to 59 Months
Enrollment: 1,195 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2014
U.S. locations: 2
States / cities: Madison, Wisconsin

Conditions: Clostridium Difficile Associated Disease
Interventions: Clostridium difficile vaccine, Placebo; Biological
Lead sponsor: Pfizer; Industry
Eligibility: 50 Years to 85 Years
Enrollment: 185 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2015
U.S. locations: 12
States / cities: DeLand, Florida • Savannah, Georgia • Stockbridge, Georgia + 9 more

Conditions: Influenza, Vaccine
Interventions: cH8/1N1 LAIV, AS03-adjuvanted cH5/1N1 IIV, cH5/1N1 IIV, AS03-adjuvanted cH8/1N1 IIV, Normal saline, Phosphate buffered saline (PBS); Biological
Lead sponsor: PATH; Other
Eligibility: 18 Years to 39 Years
Enrollment: 65 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2019
U.S. locations: 2
States / cities: Durham, North Carolina • Cincinnati, Ohio

Conditions: Influenza Prophylaxis
Interventions: Stratis Jet Injector, Needle and Syringe, 2011-2012 Fluzone trivalent inactivated influenza vaccine; Device · Biological
Lead sponsor: PharmaJet, Inc.; Industry
Eligibility: 18 Years to 59 Years
Enrollment: 83 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012
U.S. locations: 1
States / cities: Denver, Colorado

Conditions: Kidney Transplant Recipient
Interventions: Janssen Ad26.CoV2.S Vaccine, Reduction in Immunosuppression Medication, Maintenance in Immunosuppression Medication; Biological · Other
Lead sponsor: Mark Stegall; Other
Eligibility: 18 Years and older
Enrollment: 468 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 3
States / cities: Phoenix, Arizona • Jacksonville, Florida • Rochester, Minnesota

Conditions: Anthrax
Interventions: Recombinant Protective Antigen, Anthrax Vaccine Adsorbed; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: Not listed
Enrollment: 80 participants
Timeline: 2003 – 2005
U.S. locations: 1
States / cities: Baltimore, Maryland

Search by objective public record fields.

Quadrivalent HPV Vaccine to Prevent Anal HPV in HIV-infected Men and Women

A Study on the Safety and Immunogenicity of Hexavalent Influenza mRNA Vaccine in Adult Participants 50 Years of Age and Older

Pneumococcal Vaccines in Patients With Asthma

Safety of Hib-MenCY-TT Vaccine Versus Licensed Hib Conjugate Vaccine, Given at 2, 4, 6 and 12 to 15 Months of Age

Survivin Vaccine : Multiple Myeloma Autologous Hematopoietic Cell Transplant (HCT)

A Study to Evaluate Safety and Immunogenicity of the ExPEC4V Clinical Trial Material After a Single Intramuscular Dose and a Second Dose 6 Months Later in Healthy Participants Aged 18 Years and Older

Vaccine Therapy in Treating Patients With Stage IIB, Stage IIC, Stage III, or Stage IV Melanoma

Quadrivalent Influenza VLP Vaccine Dose Ranging Study in Young Adults

Tdap Vaccine Safety for Plasma Donors

Study of an HIV Preventive Vaccine Given With or Without an Adjuvant in HIV Uninfected Adults

Study of a Candidate Clostridium Difficile Toxoid Vaccine in Subjects at Risk for C. Difficile Infection

A Study of Ad26.COV2.S for the Prevention of SARS-CoV-2-Mediated COVID-19 in Adult Participants

Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Combined Measles-mumps-rubella (MMR) Vaccine in Subjects Four to Six Years of Age

Vaccine Therapy in Treating Patients With Kidney Cancer

A Study in Healthy Adults to Assess Priming With Antigenically Mismatched Live Attenuated A/H7N3 Influenza Virus Vaccine Followed by Inactivated A/H7N9 Influenza Virus Vaccine

Safety Study of HPV DNA Vaccine to Treat Head and Neck Cancer Patients

Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA Vaccine Candidate Variations in Healthy Adults

Chimpanzee Adenovirus and Self-Amplifying mRNA Prime-Boost Prophylactic Vaccines Against SARS-CoV-2 in Healthy Adults

Rates of Pertussis Disease Among Persons Receiving Pentacel® or Other Pertussis Vaccines

A Study To Investigate A Clostridium Difficile Vaccine In Healthy Adults Aged 50 to 85 Years, Who Will Each Receive 3 Doses Of Vaccine.

Safety and Immunogenicity of a Live-attenuated Universal Flu Vaccine Followed by an Inactivated Universal Flu Vaccine

Clinical Trial Assessing the Immunologic Response to a Influenza Vaccine Delivered Using an Jet Injection Device or a Needle Syringe

Janssen Ad26.CoV2.S Vaccine Booster in Kidney Transplant Recipients

Anthrax-rPA: Safety, Tolerability, Immunogenicity